Evidence map›Paper›PMID 35847846›Full record

ReviewFrontiers in oncology2022

Challenges and Opportunities for Immunoprofiling Using a Spatial High-Plex Technology: The NanoString GeoMx

Sharia Hernandez, Rossana Lazcano, Alejandra Serrano, Steven Powell, Larissa Kostousov, Jay Mehta, Khaja Khan, Wei Lu, Luisa M Solis

Abstract readReview
In one paragraph

Review in Frontiers in oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 90 papers.

0numbers the graph read from it
0cells of the map it votes in
90citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

90 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Advances in spatial omics for the analysis of prostate cancer.Analytical and bioanalytical chemistry · 2026
    Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Review
  15. Review
  16. Review
  17. Review
  18. Article
  19. Review
  20. Article

30 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Sharia HernandezDepartment of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
Rossana LazcanoDepartment of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
Alejandra SerranoDepartment of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
Steven PowellDepartment of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
Larissa KostousovDepartment of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
Jay MehtaDepartment of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
Khaja KhanDepartment of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
Wei LuDepartment of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
Luisa M SolisDepartment of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Characterization of the tumor microenvironment through immunoprofiling has become an essential resource for the understanding of the complex immune cell interactions and the assessment of biomarkers for prognosis and prediction of immunotherapy response; however, these studies are often limited by tissue heterogeneity and sample size. The nanoString GeoMx

Indexed as

biomarkersdigital spatial profilingimmune-oncologypathologytumor microenvironment

Identifiers

PMID35847846
PMCPMC9277770

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.